0001161697-20-000320.txt : 20200716 0001161697-20-000320.hdr.sgml : 20200716 20200715175951 ACCESSION NUMBER: 0001161697-20-000320 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200709 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200716 DATE AS OF CHANGE: 20200715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUTRA CORP. CENTRAL INDEX KEY: 0001512886 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 274505461 STATE OF INCORPORATION: WY FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55077 FILM NUMBER: 201030301 BUSINESS ADDRESS: STREET 1: 54 SUGAR CREEK CENTER BLVD. STREET 2: SUITE 200 CITY: SUGAR LAND STATE: TX ZIP: 77478 BUSINESS PHONE: (702) 793-4121 MAIL ADDRESS: STREET 1: 54 SUGAR CREEK CENTER BLVD. STREET 2: SUITE 200 CITY: SUGAR LAND STATE: TX ZIP: 77478 8-K 1 form_8-k.htm FORM 8-K CURRENT REPORT FOR 07-09-2020

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________

 

Form 8-K

_________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  July 9, 2020

_________________

 

Commission File Number: 0-55077

 

Neutra Corp.

(Exact name of small business issuer as specified in its charter)

 

  Wyoming   27-4505461  
  (State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.)		  
         
 

54 Sugar Creek Center Blvd., Suite 200

Sugar Land, TX

   77478  
  (Address of principal executive offices)   (Zip Code)  

 

Registrant’s telephone number, including area code: 702-793-4121

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 


Item 8.01 Other Information

 

On July 9, 2020, the Company entered an agreement with the holder of the convertible note payable dated April 30, 2016 to fully retire the principal of $49,286 and related accrued interest of $37,135 in exchange for a cash payment of $25,000. The same entity also holds the convertible notes payable dated October 31, 2015 and January 31, 2016, which are the only remaining convertible notes outstanding as of July 9, 2020. This holder has not requested any conversions of the convertible notes payable since 2016 and has agreed that they will not request any conversions of the remaining outstanding convertible notes payable until after December 31, 2020.

 

Item 9.01 Financial Statements and Exhibits

 

(d)           Exhibits.

 

99.1         Press release issued by Neutra Corp dated July 15, 2020

 

Cautionary Note Regarding Forward-Looking Statements

 

Certain of the statements contained in this report should be considered forward-looking statements. These forward-looking statements may be identified by words such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate,” “plan,” “project,” “could,” “should,” “would,” “continue,” “seek,” “target,” “guidance,” “outlook,” “if current trends continue,” “optimistic,” “forecast” and other similar words. Such statements include, but are not limited to, statements about the Company’s plans, objectives, expectations, intentions, estimates and strategies for the future, and other statements that are not historical facts. These forward-looking statements are based on the Company’s current objectives, beliefs and expectations, and they are subject to significant risks and uncertainties that may cause actual results and financial position and timing of certain events to differ materially from the information in the forward-looking statements. These risks and uncertainties include, but are not limited to, those set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (especially in Part I, Item 1A. Risk Factors and Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations), and other risks and uncertainties listed from time to time in the Company’s other filings with the SEC. There may be other factors of which the Company is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ materially from those discussed. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it may have on the Company’s operations, the demand for the Company’s products or services, global supply chains and economic activity in general. The Company does not assume any obligation to publicly update or supplement any forward-looking statement to reflect actual results, changes in assumptions or changes in other factors affecting these forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statement.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Neutra Corp.  
       
Date: July 15, 2020 By: /s/ Sydney Jim  
    Sydney Jim  
    Chief Executive Officer  

 

- 2 -

 EX-99 2 ex_99-1.htm PRESS RELEASE ISSUED BY NEUTRA CORP DATED JULY 15, 2020

 

Exhibit 99.1

 

Neutra Pays Off More Debt and Continues to Grow

 

SUGAR LAND, TX, -- Neutra Corp. (OTC: NTRR) continues to pay off more convertible debt. Since May 27, 2020, the company has not issued any new shares nor increased any debt since Nov. 4, 2019, Jim stated. On July 9, 2020, the Company entered an agreement with the holder of the convertible note payable dated April 30, 2016 to fully retire the principal of $49,286 and related accrued interest of $37,135 in exchange for a cash payment of $25,000. The same entity also holds the convertible notes payable dated October 31, 2015 and January 31, 2016, which are the only remaining convertible notes outstanding as of July 9, 2020. This holder has not requested any conversions of the convertible notes payable since 2016 and has agreed that they will not request any conversions of the remaining outstanding convertible notes payable until after December 31, 2020.

 

“Since I’ve been on board here, my goal has been to put the company into a strong financial position,” said Neutra CEO Sydney Jim. “Even when we are looking to expand and grow at a tremendous rate, when we have the ability to take out debt, it’s done.”

 

As the new facility gets in full swing, VIVIS can produce compliant, full-spectrum distillate, broad-spectrum distillate, 99%+ crystalline cannabidiol (Isolate). It’s able to extract more than 30,000 lbs per month of hemp biomass and remediate over 200 liters per month of distillate The company is also able to make a wider range of end-user CBD products than before, such as tinctures, gummies, lotions, salves, etc.

 

For inquiries about VIVIS products, White labeling, private labeling or joint ventures, please email info@viviscorp.com.

 

While the company cannot provide tours due to the proprietary manufacturing methods it employs, VIVIS has added several informative videos about hemp-based CBD extraction to its website. VIVIS filmed them at the new site. To view them, click here.

 

On the D3eSports Cup update, VIVIS Sponsored eSports Race team moves up into 3rd place in the standings after 3 weeks.  Results and schedules to be found here.  Unfortunately, round 4 this coming Sunday July 19, 2020, Jim will be on the road meeting with a few potential clients so he will not be able to participate in the race.  Please view here, to read about more updates and the global companies involved in this series.

 

About Neutra Corp.

 

Neutra Corp. (NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture—one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company’s website at https://neutrainc.com. 

 

NOTICE REGARDING FORWARD LOOKING STATEMENT 

 

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. 

 

Neutra Contact: 

 

Sydney Jim

888-433-4033

info@neutrainc.com